This clinical trial grouped 239 subjects according to their metabolic parameters (BMI, total adiposity, prevalence of T2DM, and glycated hemoglobin) and demonstrated that plasma VD concentrations did not correlate with hepatic triglyceride content, did not significantly correlate with insulin sensitivity, and did not differ from the severity of hepatic histology in patients with NASH, respectively (14). This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.